You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

You’ve been redirected to the new Cancer Care Ontario website. You can also visit the archived website, which is no longer being maintained.

The Use of FOLFIRINOX as First-Line Treatment for Metastatic Pancreatic Adenocarcinoma

ID: 2-18 Jun 2011
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
Gastrointestinal Cancer Disease Site Group

Patient Population

Adult patients with MPA who have not received prior systemic treatment for it.

Intended Guideline Users

Clinicians and healthcare providers involved in the management of patients with MPA.

Research Question(s)

Does FOLFIRINOX (folinic acid, 5FU, irinotecan and oxaliplatin) improve overall survival, progression free survival (PFS), response rate, and/or quality of life (QOL), with acceptable levels of adverse events, for adult patients with metastatic pancreatic adenocarcinoma (MPA)?

pdf download Full Report (PDF) (382.06 KB)